Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (24,258,000)	$ (15,263,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment and software development costs	1,382,000	1,095,000
Amortization of intangible assets	7,708,000	7,634,000
Amortization of operating lease right-of-use assets	636,000	541,000
(Recovery of) provision for credit losses	(20,000)	68,000
Amortization of debt issuance costs and debt discount	2,985,000	2,568,000
Investment loss (gain) from investment in Eton	3,171,000	(2,676,000)
Loss on extinguishment of debt		5,465,000
Loss on disposal of intangible assets		22,000
Stock-based compensation	12,825,000	11,521,000
Deferred income tax	643,000
Changes in assets and liabilities:
Accounts receivable	(17,453,000)	(12,287,000)
Inventories	711,000	(2,383,000)
Prepaid expenses and other current assets	(983,000)	(4,079,000)
Accounts payable, accrued expenses, accrued rebates and copay assistance	6,433,000	1,584,000
Accrued payroll and related liabilities	1,735,000	1,294,000
Deferred revenue and customer deposits	62,000	40,000
NET CASH USED IN OPERATING ACTIVITIES	(4,423,000)	(4,856,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from sale of investment in Eton Pharmaceuticals	5,510,000
Investment in patent and trademark assets	(74,000)
Purchase of product NDAs and related patents		(151,084,000)
Purchases of property, plant and equipment	(1,040,000)	(1,266,000)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	4,396,000	(152,350,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 11.875% notes payable, net of costs		4,961,000
Proceeds from Oaktree Loan, net of costs		73,552,000
Payment of debt issuance costs	(100,000)
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options	(2,362,000)	(12,971,000)
Proceeds from exercise of stock options	1,005,000	355,000
Proceeds from B. Riley senior secured note, net of costs		55,879,000
Repayment of B. Riley senior secured note		(59,750,000)
Proceeds from public offering of common stock, net of costs		64,520,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(1,457,000)	126,546,000
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,484,000)	(30,660,000)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	74,085,000	96,270,000
CASH AND CASH EQUIVALENTS AT END OF PERIOD	72,601,000	65,610,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest	15,553,000	12,279,000
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of deferred financing costs		1,950,000
Accrual of exit fee related to Oaktree Loan		2,713,000
Insurance premium financed		1,321,000
Purchase of product NDAs associated with contingent consideration payable	37,000,000
Purchase of property, plant and equipment included in accounts payable and accrued expenses	177,000	11,000
Right-of-use assets obtained in exchange for new operating lease obligations	$ 3,230,000